Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Help You Live Longer? What Mortality Trials Found

Randomized trials found fewer deaths during follow-up in the groups assigned to GLP-1 drugs. The findings do not tell us how many years of life treatment adds.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Deaths from any cause in SELECTSemaglutide4.3%Placebo5.2%Median follow-up of 3.3 years

Randomized trials found fewer deaths during follow-up among people assigned to GLP-1 drugs. The SELECT trial’s cardiovascular results apply to adults with overweight or obesity and established cardiovascular disease but without diabetes. A separate analysis of the same trial examined deaths from any cause.[2][3]

What SELECT found about deaths

Our review of deaths after respiratory infection covers a narrower outcome, including a secondary SELECT analysis. A result for deaths after infection does not establish whether the drug prevents infection.

Over a median of 3.3 years, 375 of 8,803 participants assigned semaglutide (4.3%) and 458 of 8,801 assigned placebo (5.2%) died. The hazard ratio was 0.81 (95% CI 0.71–0.93). The trial’s ordered testing plan stopped at an earlier secondary outcome, so all-cause mortality was not formally tested for superiority under that plan.[3][4]

What the pooled trials found

The study of GLP-1 use after age 80 examined health records in adults with type 2 diabetes. Check whom a study enrolled before applying its mortality findings to another group.

A 2025 analysis of 99,599 participants across randomized trials reported an all-cause mortality incidence rate ratio of 0.88 (95% CI 0.84–0.92). The authors estimated that about 121 people would need treatment over the pooled follow-up to prevent one additional death, and about 66 to prevent one major cardiovascular event. These numbers needed to treat depend on whom the trials enrolled and how long they were observed.[2]

Frequently asked

Do GLP-1 drugs help people live longer?
A review of randomized trials found fewer deaths during follow-up. That evidence applies to the populations studied and does not give an estimate of years of life gained.
Who took part in SELECT?
SELECT enrolled adults with overweight or obesity and established cardiovascular disease who did not have diabetes. It compared semaglutide with placebo.

Sources

  1. [1] Huang YN, et al. (2024). Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study Diabetes, Obesity and Metabolism. PMID 39171569
  2. [2] Galli M, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Journal of the American College of Cardiology. PMID 40892610
  3. [3] Scirica BM, et al. (2024). The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial Journal of the American College of Cardiology. Source
  4. [4] European Medicines Agency (2024). Wegovy assessment report EMA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence